Compare EPAC & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPAC | PVLA |
|---|---|---|
| Founded | 1910 | 2015 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 1994 | N/A |
| Metric | EPAC | PVLA |
|---|---|---|
| Price | $36.71 | $140.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 17 |
| Target Price | $50.50 | ★ $154.59 |
| AVG Volume (30 Days) | 283.3K | ★ 319.3K |
| Earning Date | 03-17-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.11% | N/A |
| EPS Growth | ★ 8.97 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $616,899,000.00 | N/A |
| Revenue This Year | $5.35 | N/A |
| Revenue Next Year | $5.51 | N/A |
| P/E Ratio | $102.28 | ★ N/A |
| Revenue Growth | ★ 4.65 | N/A |
| 52 Week Low | $35.01 | $18.23 |
| 52 Week High | $47.27 | $151.18 |
| Indicator | EPAC | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 28.06 | 69.33 |
| Support Level | $35.01 | $76.95 |
| Resistance Level | $38.70 | $151.18 |
| Average True Range (ATR) | 1.09 | 10.00 |
| MACD | -0.59 | 2.23 |
| Stochastic Oscillator | 18.27 | 83.76 |
Enerpac Tool Group Corp provides high-precision hydraulic and mechanical tools, controlled-force products, and heavy lifting solutions. Operating mainly through its Industrial Tools & Services (IT&S) segment, the company designs, manufactures, and distributes branded tools, and offers maintenance, bolting, machining, joint integrity, and equipment rental services across industries such as oil & gas, manufacturing, power generation, and infrastructure. Its key products include hydraulic cylinders, pumps, torque wrenches, and bolt tensioners under the brands ENERPAC and HYDRATIGHT. The company serves customers internationally, with operations in the USA, Australia, Brazil, Germany, Saudi Arabia, the United Kingdom, and other countries, deriving the majority of its revenue from the USA.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.